CBS 2019
CBSMD教育中心
中 文

Drug Coated Balloon

Abstract

Recommended Article

Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial Prospective, large-scale multicenter trial for the use of drug-coated balloons in coronary lesions: The DCB-only All-Comers Registry Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial Impact of Optimized Procedure-Related Factors in Drug-Eluting Balloon Angioplasty for Treatment of In-Stent Restenosis Percutaneous Treatment and Outcomes of Small Coronary Vessels: A SCAAR Report Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial Survival After Coronary Revascularization With Paclitaxel-Coated Balloons Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial
|<< 1 2 3 4 5 6 >>|

Consensus27 May 2020

JOURNAL：JACC: Cardiovascular Interventions Article Link

Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group

RV Jeger, S Eccleshall et al for the International DCB Consensus Group Keywords: DCB; de novo small-vessel disease; high bleeding risk; bifurcation lesions, large-vessel disease; diabetes mellitus; ACS

Full Text PDF

>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top